<table id="id_a321e9ea-3d62-4099-90aa-f5f8c7b2b10b" width="430" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption id="id_fa94a4c5-89ac-4078-9195-d048c2aa3eaf">Table 3 Established and Potential Drug Interactions: Use With Caution, Alteration in Dose or Regimen May Be Needed Due to Drug Interaction Established Drug Interactions: See Clinical Pharmacology (<linkhtml href="#i4i_pharmacokinetics_id_cdd8dcb2-d108-4cfe-8a68-f166bbdfd667">12.3</linkhtml>), Table 4 for Magnitude of Interaction.</caption>
<col width="28.1%"></col>
<col width="24.0%"></col>
<col width="47.9%"></col>
<tbody>
<tr id="id_e65d3d85-c7ea-495f-ba3e-11893ef17c4a">
<td align="left" stylecode="Botrule Toprule Rrule Lrule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Drug Name</content>
</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Effect on Concentration of Nevirapine or Concomitant Drug</content>
</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Clinical Comment</content>
</content>
</td>
</tr>
<tr id="id_c8d40f13-6bb0-441c-a5e8-313a9e0e568c">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Atazanavir/Ritonavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ Atazanavir <br/>↑ Nevirapine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Do not co-administer nevirapine with atazanavir because nevirapine substantially decreases atazanavir exposure.</td>
</tr>
<tr id="id_51df83f1-b9ae-40a9-a5fc-1d4ef1d2e0c4">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Clarithromycin</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ Clarithromycin<br/>↑ 14-OH clarithromycin</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Clarithromycin exposure was significantly decreased by nevirapine; however, 14-OH metabolite concentrations were increased.  Because clarithromycin active metabolite has reduced activity against <content stylecode="italics">
<content stylecode="emphasis">Mycobacterium avium-intracellulare complex</content>
</content>, overall activity against this pathogen may be altered.  Alternatives to clarithromycin, such as azithromycin, should be considered.</td>
</tr>
<tr id="id_e3bc1c1e-9197-43b9-8bb6-86d24afb19c3">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Efavirenz</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ Efavirenz</td>
<td align="left" stylecode="Botrule Rrule" valign="top">There has been no determination of appropriate doses for the safe and effective use of this combination [<content stylecode="italics">
<content stylecode="emphasis">see Warnings and Precautions <linkhtml href="#i4i_section_id_17116d1f-7d72-4376-82f7-4ed02f99389f">(5.4)</linkhtml>
</content>
</content>].</td>
</tr>
<tr id="id_5ef1c003-cbc2-44a3-8377-8f2ac563e585">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Ethinyl estradiol and Norethindrone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ Ethinyl estradiol<br/>↓ Norethindrone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Oral contraceptives and other hormonal methods of birth control should not be used as the sole method of contraception in women taking nevirapine, since nevirapine may lower the plasma levels of these medications.  An alternative or additional method of contraception is recommended.</td>
</tr>
<tr id="id_1bdcbd32-5135-4964-841e-2f6da97eda67">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Fluconazole</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑ Nevirapine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Because of the risk of increased exposure to nevirapine, caution should be used in concomitant administration, and patients should be monitored closely for nevirapine-associated adverse events.</td>
</tr>
<tr id="id_d2b33e7f-0f86-4771-be42-9e18f3681ade">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Fosamprenavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ Amprenavir<br/>↑ Nevirapine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Co-administration of nevirapine and fosamprenavir without ritonavir is not recommended.</td>
</tr>
<tr id="id_ce8d4013-1533-47ac-bdc7-54f8d5397335">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Fosamprenavir/Ritonavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ Amprenavir<br/>
<br/>↑ Nevirapine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">No dosing adjustments are required when nevirapine is co-administered with 700/100 mg of fosamprenavir/ritonavir twice daily.</td>
</tr>
<tr id="id_7e9b615f-f7f8-4443-bd9b-2d9422e39d22">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Indinavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ Indinavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Appropriate doses for this combination are not established, but an increase in the dosage of indinavir may be required.</td>
</tr>
<tr id="id_12d75731-ce90-4855-b6cf-61a9f8cc986d">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Ketoconazole</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ Ketoconazole</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Nevirapine and ketoconazole should not be administered concomitantly because decreases in ketoconazole plasma concentrations may reduce the efficacy of the drug.</td>
</tr>
<tr id="id_ff114206-a428-44df-a103-6967cf72814b">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Lopinavir/Ritonavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ Lopinavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>A dose increase of lopinavir/ritonavir tablets to 500/125 mg twicedaily is recommended when used in combination with nevirapine. A dose increase of lopinavir/ritonavir oral solution to 533/133 mg twice daily with food is recommended in combination with nevirapine.</paragraph>
<paragraph>In children 6 months to 12 years of age receiving lopinavir/ritonavir solution, consideration should be given to increasing the dose of lopinavir/ritonavir to 13/3.25 mg/kg for those 7 to &lt;15 kg; 11/2.75mg/kg for those 15 to 45 kg; up to a maximum dose of 533/133 mg twice daily.</paragraph>
<paragraph>Refer to the lopinavir/ritonavir package insert for complete pediatric dosing instructions when lopinavir/ritonavir tablets are used in </paragraph>combination with nevirapine.</td>
</tr>
<tr id="id_b28ec464-9972-4ee6-9917-dd8619196bb0">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Methadone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ Methadone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Methadone levels were decreased; increased dosages may be required to prevent symptoms of opiate withdrawal.  Methadone-maintained patients beginning nevirapine therapy should be monitored for evidence of withdrawal and methadone dose should be adjusted accordingly.</td>
</tr>
<tr id="id_51322573-b031-40aa-bd47-20ce9640bf0d">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Nelfinavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ Nelfinavir M8 Metabolite<br/>↓ Nelfinavir C<sub>min</sub>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The appropriate dose for nelfinavir in combination with nevirapine, with respect to safety and efficacy, has not been established.</td>
</tr>
<tr id="id_81040776-de62-40d1-ae25-4cb225ca260f">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Rifabutin</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑Rifabutin</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Rifabutin and its metabolite concentrations were moderately increased.  Due to high intersubject variability, however, some patients may experience large increases in rifabutin exposure and may be at higher risk for rifabutin toxicity.  Therefore, caution should be used in concomitant administration.</td>
</tr>
<tr id="id_edfadf8c-b9cb-469f-8940-19586ee2ff53">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Rifampin  </td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓ Nevirapine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Nevirapine and rifampin should not be administered concomitantly because decreases in nevirapine plasma concentrations may reduce the efficacy of the drug.  Physicians needing to treat patients co-infected with tuberculosis and using a nevirapine-containing regimen may use rifabutin instead.  </td>
</tr>
<tr id="id_d46c3d91-44fd-409f-93c9-0b2000bc1491">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Saquinavir/ritonavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The interaction between Nevirapine and saquinavir/ritonavir has not been evaluated</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The appropriate doses of the combination of nevirapine and saquinavir/ritonavir with respect to safety and efficacy have not been established. </td>
</tr>
<tr id="id_1a9267cc-5cbb-42be-a0dc-0edaa5f6cd9f">
<td align="left" colspan="3" stylecode="Lrule Botrule Rrule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">
<content stylecode="italics">
<content stylecode="emphasis">Potential</content>
</content> Drug Interactions: </content>
</content>   </td>
</tr>
<tr id="id_4f362df2-6f7f-4aab-888f-b9529b909864">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Drug Class</content>
</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">
<content stylecode="emphasis">Examples of Drugs</content>
</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top"> </td>
</tr>
<tr id="id_5a6ddc9d-b239-49da-bb46-ee7ffcefa536">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Antiarrhythmics</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Amiodarone, disopyramide, lidocaine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Plasma concentrations may be decreased.</td>
</tr>
<tr id="id_68e398cc-c239-4de0-bf86-3427e69aefd7">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Anticonvulsants</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Carbamazepine, clonazepam, ethosuximide</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Plasma concentrations may be decreased.</td>
</tr>
<tr id="id_57a631fb-0bb3-4d02-8f72-680a36315b0b">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Antifungals</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Itraconazole</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Plasma concentrations of some azole antifungals may be decreased. Nevirapine and itraconazole should not be administered concomitantly due to a potential decrease in itraconazole plasma concentrations.</td>
</tr>
<tr id="id_fa1c4b56-74cc-4a42-8f6c-288a0ad89a5b">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Calcium channel blockers</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Diltiazem, nifedipine, verapamil</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Plasma concentrations may be decreased.</td>
</tr>
<tr id="id_a82e60fe-5790-456d-8cb9-59ef8eac765c">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Cancer chemotherapy</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Cyclophosphamide</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Plasma concentrations may be decreased.</td>
</tr>
<tr id="id_b02f60f5-fa87-4e62-a860-a618e047dbe4">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Ergot alkaloids</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Ergotamine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Plasma concentrations may be decreased.</td>
</tr>
<tr id="id_16604fd0-34fb-4e0a-bfb8-bac6f15743bf">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Immunosuppressants</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Cyclosporin, tacrolimus, sirolimus</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Plasma concentrations may be decreased.</td>
</tr>
<tr id="id_24fa9e96-4b45-4ba7-bb3a-c2b04977688a">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Motility agents</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Cisapride</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Plasma concentrations may be decreased.</td>
</tr>
<tr id="id_b2421eb3-d4f7-4fef-a139-dcd271ea9615">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Opiate agonists</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Fentanyl</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Plasma concentrations may be decreased.</td>
</tr>
<tr id="id_50205d33-7dad-467b-97c5-152582754400">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">Antithrombotics</td>
<td align="left" stylecode="Rrule" valign="top">Warfarin</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Plasma concentrations may be increased. Potential effect on anticoagulation. Monitoring of anticoagulation levels is recommended.</td>
</tr>
</tbody>
</table>